Novo Nordisk's experimental drug fails to reduce heart attacks and strokes in large study

Novo Nordisk's experimental drug, ziltivekimab, failed to reduce the risk of heart attacks and strokes in a large Phase 3 trial of over 6,300 patients with heart and kidney disease. The failure, which caused Novo's shares to drop ~7%, casts doubt on the strategy of targeting inflammation for cardiovascular disease, despite the drug successfully lowering inflammation markers. The result is a blow to the company's growth plans beyond diabetes and obesity.

Ziltivekimab trial failure

• ▪Following the announcement on July 31, 2026, shares in Novo Nordisk fell by about 7%
• ▪Novo Nordisk's experimental anti-inflammatory drug, ziltivekimab, failed to reduce the risk of major heart events in a large Phase 3 study
• ▪The trial failure is considered a blow to Novo Nordisk's growth prospects beyond its obesity and diabetes drugs
• ▪The study's primary goal was to reduce the risk of cardiovascular-related death, heart attack, or stroke

Inflammation targeting approach

• ▪The result raises questions about the viability of targeting inflammation to prevent cardiovascular complications
• ▪Although the trial failed its primary goal, ziltivekimab did successfully lower markers of inflammation in patients

Patient population studied

• ▪Trial participants were people with existing heart disease, kidney disease, and inflammation
• ▪The pivotal Phase 3 study for ziltivekimab enrolled over 6,300 participants